St Jude Childrens Research Hospital
American Cancer Society names Medal of Honor recipients
American Cancer Society presented its Medal of Honor to three individuals.
Cure for childhood cancer may come at the cost of premature aging
Patient survival is the overarching goal of all cancer treatments, and improvements in survival that have been achieved over the years are an unequivocal victory for oncology.
Survivors of childhood acute lymphoblastic leukemia at higher risk for type 2 diabetes
Survivors of childhood acute lymphoblastic leukemia, particularly those with obesity and/or who received treatment during adolescence, appeared to be at higher risk for type 2 diabetes than the general population, according to study results published in Cancer.
Integrated genome, transcriptome sequencing identifies subtypes of AML, myelodysplastic syndrome
ORLANDO — The integration of transcriptomic and genomic sequencing data from a large cohort of adults with acute myeloid leukemia or myelodysplastic syndromes allowed for the identification of subtypes and constellations of driver mutations, according to study results presented at ASH Annual Meeting and Exposition.
Vincristine shortage underscores vulnerability of ‘fragile market’ for crucial treatments
A shortage of the chemotherapy drug vincristine, which is essential to the treatment of most pediatric cancers, has left the oncology community struggling to find short-term solutions while recognizing the need for long-term reform.
T-cell Responses to Concurrent HIV and Herpesvirus Infections
An observational, prospective cohort study to discover new information about how HIV and herpes viruses interact with the immune system, with a goal of learning more about how T cells in the immune system respond to and fight off long-term (chronic) viruses, in order to improve medical care in the future.
TCR-engineered T Cells in Solid Tumors (ACTengine)
NY-ESO-1 TCR Engineered T Cell and HSC After Melphalan Conditioning Regimen in Treating Participants with Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Phase 1, open-label study evaluating the safety and efficacy of adoptive transfer of autologous NY-ESO-1 CD8-TCR engineered T cells and NY-ESO-1 CD4-TCR engineered hematopoietic stem cells after a myeloablative conditioning regimen, with administration of IL-2 in patients with relapsed or treatment-refractory ovarian, fallopian tube or primary peritoneal cancer.